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ABSTRACT
Background Data: Glucocorticoid-induced osteoporosis is a well-known significant health problem
worldwide that causes morbidity and mortality. Glucocorticoid-induced vertebral compression fracture
is one of the most common types of osteoporotic fractures associated with significant morbidities such
as severe agonizing pain, limited mobility, and spinal deformity. Percutaneous vertebroplasty (PV) can
be performed in the treatment of refractory back pain in these cases of osteoporotic vertebral fractures
(OVFs) without significant complication when conservative treatment fails.
Purpose: To evaluate the clinical and radiographic outcomes of thoracolumbar OVFs treated with PV in
adult osteoporotic patients with long-term corticosteroid therapy.
Study Design: Retrospective clinical case series.
Patients and Methods: Twenty-eight patients with painful steroid-induced OVFs underwent vertebroplasty
in 61 vertebral levels. Inclusion and exclusion criteria were applied. Preoperatively, all patients were
subjected to intensive diagnostic workups, including history taking and clinical and radiological
examinations, such as CT scan and MRI. The procedure was guided by C-arm and considered complete
when the unfilled area was less than 25% of the vertebral body height in the lateral radiograph. Visual
Analogue Scale (VAS) and Oswestry Disability Index (ODI) were used to assess pre- and postoperative
back pain and functional status of our patients.
Results: Seventeen patients (60.71%) were males and eleven patients (39.28%) were females. The mean
age was 57 ± 5.04 (range, 49–68) years. The mean follow-up of the patients was 38.4 2± 11.16 (range,
24–60) months. Overall, 61 levels were reported including 10 patients (39%) with a single level and 18
patients (61%) with two levels or more as follows: two levels in eight patients, three levels in six patients,
four levels in three patients, and one patient with five levels. The most common affected region was the
thoracolumbar junction (T11, T12, and L1) in 38.69%. Back pain VAS decreased from 7.29 ± 1.04 before
vertebroplasty to 3.25 ± 0.75 one week after vertebroplasty, 1.68 + −0.66 at 12 months postoperatively, and
3.11 ± 1.13 at final follow-up 24 months postoperatively (p < 0.001). ODI improved from 40.82 ± 12.32
(range, 14–66) preoperatively to 16.68 ± 3.19 (range, 10–24) at 12 months postoperatively and 20.92 ± 4.66
(range, 10–30) at final follow-up 24 months postoperatively (p < 0.00)
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Conclusion: This study suggests that fast and substantial pain relief and quality of life improvement could
be achieved after percutaneous vertebroplasty in most patients of glucocorticoid induced osteoporotic
vertebral fractures. These improvements could be maintained up to one year, however this effect decline
with time due to the progressive nature of the underlying disease.
(2020ESJ209)
Keywords: Osteoporotic vertebral fractures (OVFs); Glucocorticoids; Vertebroplasty; Thoracolumbar
spine.

INTRODUCTION
Glucocorticoid-induced osteoporosis is a wellknown significant health problem worldwide
leading to morbidity and mortality. Glucocorticoidinduced vertebral compression fracture (G-OVF)
is a common type of osteoporotic fractures
associated with significant morbidities such as
severe pain, limited mobility, and spinal deformity.1
The pathogenesis of steroid-induced osteoporosis
is complex, including reduced bone formation and
increased bone resorption. The fracture risk in
cases of OVFs is mainly related to time and dosage
of glucocorticoids (i.e., the higher the dosage and
the longer the treatment, the greater the risk).23
Primary osteoporotic vertebral compression
fracture affects mainly the elderly and
postmenopausal women,33 whereas G-OVF affects
men more frequently and the affected age group is
relatively younger.39 The main presenting symptom
in patients with G-OVFs is back pain which is
associated in most cases with limited daily activity
and kyphotic deformity; however, vertebral height
loss is the main radiological sign.35
Patients with glucocorticoid osteoporosis, such
as chronic obstructive pulmonary disease,
rheumatoid arthritis, and leprosy, cannot tolerate
bracing.35 Regardless of the use of corticosteroids,
the inflammation itself has a harmful effect on
bone remodeling by increasing bone resorption
and decreasing the formation. Rheumatoid
arthritis alone doubles the vertebral fractures.24
The risk of fractures is increased up to 2.6 and the
global prevalence of vertebral fractures in patients
receiving long-term glucocorticoids has been
reported to be 37%.35,36
42

Percutaneous vertebroplasty (PV) was introduced
in 1987 by Gailbert and Diamond for the treatment
of large spinal hemangioma. It is an image-guided
minimally invasive procedure through which
the polymethylmethacrylate (PMMA) cement is
injected into the fractured vertebra.7 The surgical
metallic fixation of the osteoporotic spine with
long-term use of glucocorticoids has usually failed
because of poor bone quality and comorbidities
that preclude prolonged anesthesia.23,39 VP should
be considered in patients who suffer from severe
persistent pain despite adequate conservative
treatment for at least three weeks.23
This study aims to evaluate clinically and
radiographically thoracolumbar OVFs treated
with VP in adult osteoporotic patients with longterm use of corticosteroid therapy.

PATIENTS AND METHODS
We retrospectively reviewed the medical records
of all subacute cases of OVFs due to longterm use of steroid therapies that underwent
operations in the Orthopedic Department, Kafr
El-Sheikh University Hospital, and Neurosurgery
Department, Zagazig University Hospital,
between January 2012 and December 2017.
We traced 28 patients with painful OVFs who
underwent VP at 61 levels with complete clinical
and radiological data. The mean follow-up of the
patients was 38.42 ± 11.16 (range, 24-60 months).
Inclusion criteria for the current study were as
follows: (1) patients recently diagnosed with
OVFs due to long-term therapy of corticosteroids
and failed medical treatment for 3–6 weeks
with persistence of pain; (2) confirmed cases
of osteoporosis by Dual Energy X-ray

Egy Spine J - Volume 35 - July 2020

The

EGYPTIAN SPINE
Journal
Absorptiometry (DEXA) with T-score of −2.5 or
less; (3) patients with preoperative pain intensity
according to Visual Analogue Scale (VAS) ≥ 5;
(4) levels from T5 down to L5, and patients with
incomplete data. On the other hand, exclusion
criteria included the following: (1) patients with
G-OVFs for more than three months; (2) patients
with infection, coagulopathies, tumor, or trauma;
(3) those who had a neurological deficit.
Relative contraindications included improved
cases on conservative treatment with VAS less
than 5, vertebral body collapse more than 75%,
posterior vertebral wall destruction involvement
(for fear of cement leakage), and any level above
T5 because image guidance is difficult due to
shoulder shadow, making the procedure unsafe
with the risk of cement leakage and neurological
deficit, the smaller targets are more difficult to
cannulate accurately, and the risk of neurologic
damage from needle placement or PMMA
migration increases.
Preoperatively, routinely, an intensive diagnostic
workup was performed in all patients. It included
medical history, clinical assessment including VAS
for the back pain and ODI for functional status, and
radiological examination such plain radiographs,
CT scan, and MRI. MRI thoracolumbar spine
was essential for diagnosing recent fractures
(vertebral edema), excluding malignant lesions,
and detecting canal compromise.
Surgical Technique
Patients were placed prone on a radiolucent table,
and the procedure was performed under local
anesthesia and sedation. Under C-arm guidance
in anteroposterior (AP) and lateral views, a large
Jamshidi needle, typically 10 or 11 G for lumbar
and 8 G for thoracic vertebra with a beveled
tip, was used to puncture the fractured vertebra
through the pedicles. The needle moves parallel to
the superior and inferior edges of the pedicle or in
a slightly descending course through the pedicle.
The needle was advanced toward the anterior third
of the vertebral body under fluoroscopic guidance;
it needed 5 to 7 minutes to mix the radiopaque
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cement to be ready and inject into the vertebral
body using small 1 cc insulin syringes or a cement
gun under continuous fluoroscopic monitoring
(Figures 1 and 2).
In most cases, between 3 to 4 mm cement has
been used (3 to 4 insulin syringes) per level. The
procedure was terminated immediately if cement
reached the posterior quarter of the vertebral
body or if significant leakage into the disc space
occurred. If the unfilled area was more than 25% of
the vertebral body height in the lateral radiograph,
another needle was inserted from the contralateral
side with the needle aiming at the unfilled area.
The procedure was considered complete when the
unfilled area was less than 25% of the vertebral
body height in the lateral radiograph. Skin closure
was done using single sutures (Figure 3).
Postoperatively, following PVP, the patient was
kept in the supine position in bed for 4 hours and
after that, could ambulate with assistance and a
postoperative X-ray was performed. The patient
was observed and discharged on the same day.
Postoperative Outcome Evaluation
Clinical Assessment. All patients were evaluated
at our outpatient clinic at 1 week, 6 weeks, 6
months, 1 year, and 2 years postoperatively or as
recommended in complicated patients. Overall
back pain and functional status (quality of life)
were assessed with VAS and ODI, respectively,
and any neurological or systemic complications
were reported.
Radiological Evaluation. Postoperative plain
radiographs and CT-scans were used to measure
the anterior vertebral height of cemented
vertebrae, the quantity of bone cement used,
cement extravasation, and new level vertebral
fractures.
Statistical Analysis
Collected data were statistically compared using
tests from the Statistical Package for the Social
Sciences (SPSS) program version 17 (Chicago,
Illinois, USA). Analysis of Variance (ANOVA)
test was used and p value ≤ 0.05 is considered
significant.
43
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RESULTS
Twenty-eight patients, with 61 levels, were
retrospectively included in this study. Seventeen
patients (60.71%) were males and 11 patients
(39.28%) were females. The mean age was
57 ± 5.04 (range, 49–68) years. Ten patients (39%)
had a single level and 18 patients (61%) had two
levels or more (2 levels in 8 patients, 3 levels in 6
patients, 4 levels in 3 patients, and 5 levels in 1
patient) (Table 1). Treated levels were distributed
nonuniformly from T5 to L5, and 24 (39.33%) of
the 61 fractures occurred at the thoracolumbar
junction (T11 to L1) (Table 2). The patient with the
affected five levels was contagious and managed
in consecutive sessions. The mean cement volume
was 3.58 ± 0.557 mm (range, 3–5.8 mm) cement
per vertebra.
Sixteen patients (57%) had previously sustained at
least one fragility fracture, and 43% were actively
receiving osteoporosis treatment (primarily
oral bisphosphonates) at the time of entry into
the study. All patients had previously received
systemic steroid medications for at least 6 months,
and 61% were currently taking steroids.
The preoperative mean anterior vertebral
body height was 17.22 ± 2.10 and increased
to 17.57 ± 2.80 one month postoperatively;
Table 1. Number of vertebral segments affected per
patient.
Level
affected

Number

Total
number

Single
level

10 patients (10 levels)
2 levels 8 patients

Multiple
levels

3 levels 6 patients
4 levels 3 patients
5 levels 1 patient

44

18 patients
(51 levels)

28 patients
(61 levels)

the difference was statistically insignificant
(p = 0.408). Pain assessed by the VAS significantly
decreased from 7.29 ± 1.04 before vertebroplasty
to 3.25 ± 0.75 one week after surgery (p < 0.001)
and improved to 3.11 ± 1.13 at the final follow-up
(Table 3) (p < 0.001). ODI improved significantly
from 40.82 ± 12.32 (range, 14–66) preoperatively
to 25.64 ± 5.22 (range, 16–36) postoperatively
(p < 0.0001) and 20.92 ± 4.66 (range, 10–30) at the
final follow-up (p < 0.0001) (Tables 4 and 5).
Asymptomatic cement extravasation was seen in 7
levels (11, 47%). Four of the 7 leaks were in adjacent
disc spaces, and each leak had been anticipated
preoperatively based on the recognition of endplate
disruption as seen on preoperative CT. Two small
leaks in the anterolateral segmental vein were
detected intraoperatively but did not embolize or
preclude the completion of the procedure. Another
small ventrolateral soft-tissue leak was detected
on scans made a week postoperatively. No cement
leak was symptomatic. There were no significant
relationships between cement extravasation and
the quantity of cement used, the number of levels
augmented, and other locations (thoracic or
lumbar) (p > 0.05 for all comparisons). No serious
complications were reported in this study, except
for one case of wound infection and another case
of postoperative radiculopathy, both relieved by
medical treatment.
Table 2. Demographics of the most common region.
Level
T5
T6
T7
T8
T9
T10
T11
T12
L1
L2
L3
L4
L5
Total

Single
1
1
1
1
1
1
1
1
1
1
10 levels

Multiple
4
1
3
3
1
5
6
8
7
3
4
4
2
51 levels

Total
5
1
4
4
1
6
7
9
8
4
5
5
2
61 levels

%
8.19%
1.63%
6.55%
6.55%
1.63%
9.83%
11.47%
14.75%
13.11%
6.55%
8.19%
8.19%
3.27%
100%
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Table 3. Pain assessed by Visual Analogue Scale (VAS) and function by Oswestry Disability Index (ODI).
Parameters

Preoperative

1 week postop

6 weeks
postop

6 months
postop

12 months
postop

24 months
postop

VAS*

7.29 ± 1.04
(5–9)

3.25 ±0 .75
(2–5)

3.17 ± 0.77
(2–6)

2.21 ± 0.57
(1–3)

1.68 ± 0.66
(1–3)

3.11 ± 1.13
(1–5)

NA

NA

16.68±3.19
(10–24)

20.92 ± 4.66
(10–30)

40.82 ± 12.32
25.64 ± 5.22
(14–66)
(16–36)
*Pre- versus all postoperative p < 0.000
**Pre- versus all postoperative p < 0.000
ODI**

Figure 1. A 54-year-old female
with chronic rheumatoid taking
glucocorticoid medications had OVFs
of different levels with severe pain
and did not respond to conservative
treatment for 4 weeks. (A,B)
X-ray lateral and AP views of the
lumbosacral spine revealed 4 OVFs
(D12, L1, L2, and L4). (C,D) X-ray AP
and lateral views of the same patient
showed vertebroplasty with unilateral
segmental vessel embolization at
L4 with no adverse effects. (E,F)
X-ray AP and lateral views one year
later with continuous glucocorticoid
medication, she came complaining of
severe LBP opposite L3, and we did
another vertebroplasty for L3.
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Figure 2. A 64-year-old glucocorticoiddependent male patient with chronic
asthmatic bronchitis developed OVF
in T12 and vertebroplasty has been
conducted with 5-year follow-up. (A,B)
X-ray AP and lateral views of the
thoracolumbar spine revealed OVF of
T12. (C,D) CT for the same patient after
one month of medical treatment with
severe pain and he became bedridden.
(E,F) X-ray AP and lateral views
immediately after VP for T12. (G,H)
X-ray AP and lateral views at oneyear follow-up after VP for T12. (I,J)
X-ray AP and lateral views at five-year
follow-up after VP for T12. (K,L,M) CT
scanning of the same patient at five-year
follow-up after VP for T12.

Figure 3. A 58-years-old lady with long-term use of glucocorticoid treatment for leprotic lesions developed OVF
opposite T8 and medical treatment with rest for 2 months was applied and then she developed further severe pain
following minor trauma in the same area when MRI was performed to show three levels of OVFs, for which we
conducted VP. (A) X-ray lateral view of the dorsal spine revealed OVF of T8. (B,C) MRI sagittal view of the patient
2 months later with 3 levels affected T8-T9-T10. (D,E) X-ray anteroposterior and lateral views of the dorsal spine
after VP of these levels.
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DISCUSSION
Glucocorticoid-induced OVFs are one of the
most common types of osteoporotic fractures in
clinical practice but have received little attention.
It has been estimated that up to 17% of OVFs in
the population can be attributed to the chronic
oral corticosteroids use, even at small doses as
low as 2.5 mg per day.6 One of the most possible
side effects of the usage of glucocorticoids is the
trabecular bone mass loss.11,28
Back pain at different intensities is the main
presenting symptom in all patients of G-OVFs.
Mild-to-moderate degree of pain in cases of acute
vertebral osteoporotic fracture can be relieved by
bed rest, bracing, analgesics, anti-osteoporotic
drugs (bisphosphonates or denosumab), and
anabolic drugs as tripartite (Forteo);23,38 however,
advanced cases with compression fractures mostly
need intervention.23 PV should be considered in
patients who suffer from severe persistent pain
even after at least three weeks of conservative
treatment.1,23
Twenty-eight patients (17 males and 11 females)
with 61 vertebral levels were treated with PV.
The mean age was 62.50 ± 7.09 years, which
is consistent with the literature reporting that
patients of osteoporotic spine due to long-term
use of corticosteroid therapy treated with PV were
significantly younger and more likely to be males
compared to those with primary osteoporosis.23,30
Severe persistent back pain was the main
presenting symptom in all patients in the current
study; the pain was assessed using VAS which was
significantly (p < 0.001) decreased from a mean of
7.29 ± 1.04 preoperatively to a mean of 3.17 ± 0.77
6 weeks postoperatively, which is in agreement
with most studies addressing the same issue.23,30
Although in this study, a significant decrease
of VAS was observed at the final follow-up at
24 months compared to preop VAS value, we
reported a significant increase of VAS value at the
final follow-up compared to that at 12 months;
this final increase of VAS was mainly due to the
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nature of secondary osteoporosis, maintenance
of corticosteroids in high dose, and the newly
developed vertebral compression fractures during
the two-year follow-up.
The efficacy of vertebroplasty in OVFs in relieving
pain and improving the functional status has
been discussed in many studies with reported
effectiveness up to 90%.23 The mechanisms of
pain relief following PV include the following:
stopping vertebral micromotion which could be
achieved by cement injection and stabilization
of microfractures20,40 and cement polymerization
process, which can lead to a high temperature
sufficient to cause protein denaturation, cell
necrosis, and nerve ablation.5,13
In this study, ODI improved significantly from
a mean of 40.82 ± 12.32 (14–66) preoperatively
to a mean of 16.68 ± 3.19 (10–24) at 12 months
postoperatively and 20.92 ± 4.66 (10–30) two
years postoperatively (p < 0.000), consistent with
other similar studies.23
Although PV has a successful overall outcome
in the literature, it is associated with some local
and systemic complications with an overall rate
of < 1% in those osteoporotic fractures.3 The
most common complications are cement leakage
beyond the vertebral body margins, into vascular
and surrounding structures, new levels of vertebral
compression fractures, pulmonary distress, and
infection.17 Patients with steroid-induced OVFs
experienced the same degree of significant pain
relief and complications after PVP as those not
receiving corticosteroids.23
Cement Leak
In clinical practice, leakage is more common
and frequent in pathological osteolytic vertebral
fractures, and mostly the cement leak noticed in
steroid-induced osteoporotic OVFs is local and
asymptomatic 16,30; however, it could be serious in
cases of extravasation into the vertebral canal or
the neural foramen in large volume causing cord
or nerve root compression.18,38
Many factors are controlling the percentage of
cement leak during VP, such as the volume and
viscosity of the cement, vertebral bone status, the
47
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pressure used, and even the operator. Jima et al.14
reported cement leak in 8% of PVP procedures
in cases of VCFs, while Yang et al.40 noticed an
overall higher percentage of cement leakage up to
36.44%.
In this study, asymptomatic cement extravasation
was seen in 7 of the 61 levels treated (11.49%),
which is comparable to other series 23 with a
reported cement leakage rate of 13.51% into the
disc space and the paravertebral tissue. Four of
the 7 leaks were in adjacent disc spaces and two
small leaks into an anterolateral segmental vein,
detected intraoperatively but did not embolize
the operation, and the procedure was finished
smoothly. Another small anterolateral soft-tissue
leak was detected on the postoperative scan. No
cement leak was symptomatic or serious.
In general, the presence of cortical disruption, the
amount of PMMA bone cement and its viscosity
are important independent risk factors for the
occurrence of cement leak13,18 but severe vertebral
fracture with marked height loss and the presence
of vertebral clefts are specific risk factors for intradiscal cement leak.31
The mean volume of the injected cement was
3.58 ± 0.557 ml (range, 3–5.8 ml), and this
correlated with most studies reporting that a
volume of about 3 ml of cement was enough to
alleviate the associated pain.19,25
Hitwatashi et al.10 found that the volume of the
injected cement may also be important when
discussing the leakage; the more the volume,
the more the risk of leakage, especially with
low-viscosity cement. Although low-viscosity
cement is good for spreading into the trabecular
bone, the risk of extravasation is high. In
contrast, higher-viscosity cement forms a more
solid mass with more trabecular disruption but
reduces leakage incidence; therefore, cement
with doughy consistency and medium viscosity
is recommended. Still, in cases of severe types
of fractures with cortical disruption, the high
viscosity one is the solution to minimize cement
leak. 40 Intradiscal cement leakage should be
avoided because there is an association between
48

adjacent level compression and intradiscal cement
leak.12,29
New Vertebral fracture
The occurrence of new OVFs in patients of steroidinduced vertebral fractures was discussed widely;
some clinical studies11,24,36 reported an increased
incidence of new OVFs following vertebroplasty
and others15,23 stated that the rate is the same
without a difference.
Koch et al.23 and others9,15 reported that patients
with G-OVFs experience levels of pain relief and
development of new fractures after PV similar to
those with primary osteoporotic vertebral fractures.
There was another study 28 stating that adverse
effects on bone are mainly due to underlying
autoimmune or inflammatory disorders. The
previous results support the use of PV to treat
OVFs unresponsive to conservative management
in patients receiving long-term corticosteroid
therapy.
Numerous studies in the literature suggest a
higher rate of new vertebral fractures after
vertebroplasty in G-OVFs compared to those not
using steroids.11.24,30,36 Syed et al.36 reported that the
rate was twice that of patients not taking steroids
and others studies stated that the incidence of
newly developed vertebral fractures increased
by approximately 30%–50% in patients using
corticosteroids for more than 3 months, which
is consistent with the rate in our study indicating
that new vertebral fractures developed in 39% of
the patients. Steinbuch et al.35 demonstrated that
the increased rates of symptomatic new vertebral
fractures were closely associated with higher
dosages, longer durations, and continuous usage
of glucocorticoids rather than the procedure of
vertebroplasty; Kaji et al.16 observed that the risk of
fractures for the same bone mineral density (BMD)
was higher in G-OVFs than in postmenopausal or
senile osteoporosis.
Due to the nature of secondary osteoporosis
and the maintenance usage of large doses of
corticosteroids in our patients, it is expected to
find new vertebral compression fractures in a
high percentage during the follow-up and we also
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reported a mild increase of the VAS value and ODI
at final 24-month follow-up after they were being
decreased at 12 months postoperatively (VAS
was 1.68±0.6 and 3.11±1.13 at 12 months and 24
months; ODI was 16.89 ± 3.15 and 21.20 ± 0.914
at 12 and 24 months postoperatively, resp.).
Moreover, the effects of PV to the adjacent
nonaugmented levels in patients with G-OVFs
were also discussed in detail. Some clinical
studies8,26 reported an increased rate of new OVFs
after vertebroplasty due to the pressure created
by the stiffness of the cemented vertebrae on the
adjacent ones and others22,31 demonstrated that
there was no relation and excluded PV from the
risk factors for new OVFs and they developed with
conservative treatment. The mechanical effects of
vertebroplasty on injured and adjacent vertebrae
may also be influenced by the characteristics of
the treated spine, such as BMD, the type, fracture
severity, and disc degeneration.22 Therefore, PV
is not a risk factor for new osteoporotic vertebral
compression fracture, which occurs even with
conservative treatment.22
In summary, vertebroplasty is generally a safe and
effective procedure to control pain associated with
fractures of the spinal column. Many complications
can occur and are likely to pass underreported
or without serious effect. Proper technique can
minimize the risk of PMMA migration. The
learning curve should be moderately quick and
safe if physicians familiarize themselves with
these axioms. Due to the progressive nature of
the disease, the effect of PV decline with time in
patients with G-OVFs.
Large prospective, randomized, controlled
studies with long-term follow-up are important
and warranted for proper evaluation of the
procedure for G-OVFs and to report any possible
complications from cement-bone junction
reaction, new and recurrent vertebral fractures.
Minimizing PV complications depends on the
following factors: good selection of the patients,
good learning curve, high radiologic resolution,
and proper cement polymerization state.
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CONCLUSION
This study suggests that fast and substantial pain
relief and quality of life improvement could be
achieved after percutaneous vertebroplasty in most
patients of glucocorticoid induced osteoporotic
vertebral fractures. These improvements could
be maintained up to one year, however this effect
decline with time due to the progressive nature of
the underlying disease.
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الملخص العربى
دور رأب العمود الفقري في كسور هشاشة عظام الفقرات التي يسببها الستيرويد

البيانـات الخلفيـة :هشاشـة العظـام المسـتحثة بالجلوكوكورتيكويـد هـي مشـكلة صحيـة كبيـرة معروفـة فـي جميـع
أنحـاء العالـم قـد تسـبب االعتلال والوفـاة .الكسـر االنضغاطـي الفقـري الناجـم عـن الجلوكوكورتيكويـد هـو أحـد أكثـر
شـيوعا والتي ترتبط بأمراض كبيرة مثل األمراض المسـببة لأللم الشـديد  ،ومحدودية
أنواع كسـور هشاشـة العظام
ً
الحركـة  ،وتشـوه العمـود الفقـري .ان إجـراء جراحـة رأب العمـود الفقـري عـن طريـق الجلـد يمكـن اسـتخدامه بكفـاءة
وفعاليـة فـي حـاالت  G-VFsلعلاج آالم الظهـر المقاومـة دون مضاعفـات كبيرةعندمـا يفشـل الحـل التحفظـى وال
يمكن اجراء التثبيت بواسطه المسامير.
الغرض :التقييم السـريري واإلشـاعي لكسـور العمود الفقري الصدري و القطني التي يتم عالجها عن طريق جراحة
رأب العمـود الفقـري عـن طريـق الجلـد فـي مرضـى هشاشـة العظـام البالغيـن الذيـن يعانـون من أمراضيتـم العالج لها
بالكورتيكوستيرويد لفترة طويلة.
تصميم الدراسة :سلسلة الحاالت السريرية بأثر رجعي.

المرضـى والطـرق :خضـع ثمانيـة وعشـرون مريضـا يعانـون مـن كسـور بالفقـرات نتيجـه هشاشـه مسـتحثه باسـتخدام
االسترويدز لعملية رأب العمود الفقري في واحد وستين مستوى من مستويات العمود الفقري .تم تطبيق معايير
التضميـن واالسـتبعاد .قبـل الجراحـة  ،يتـم إجـراء الفحوصـات التشـخيصية المكثفـة فـي جميـع المرضـى بمـا فـي ذلـك
التاريخ والفحص السريري واإلشعاعي والمسح المقطعي .في بعض األحيان  ،يتم إجراء التصوير بالرنين المغناطيسي
للعمود الفقري الصدري والقطني لفحص العظام .وتتم اإلجراءات الموجه بواسطة السي أرم لتحديد درجة الحشو
مكتمل عندما كانت المساحة الخالية أقل من  25٪من ارتفاع الجسم الفقري في
ً
المقبولة .و قد تم اعتبار اإلجراء
الصورة األشاعية الجانبية.
النتائـج :سـبعة عشـر مريضـا مـن الذكـور ( )60.71٪و  11مريضـا مـن اإلنـاث ( )39.28٪متوسـط العمـر ()5.04±57
68-49سـنة مـع واحـد وسـتين مسـتوى متأثـرا  ،عشـرة مرضـى ( )39٪بمسـتوى واحـد وثمانيـة عشـر مريضـا ()61٪
بمستويين أو أكثر على النحو التالي (مستويان في ثمانية مرضى  ،ثالثة مستويات في ستة مرضى  ،أربعة مستويات
شـيوعا هـي المنطقـة
فـي ثالثـة مرضـى ومريـض واحـد فقـط بخمـس مسـتويات) .كانـت المنطقـة المصابـة األكثـر
ً
الصدريـة القطنيـة ( )T11،T12،L1فـي ( ، )38.69٪انخفـض األلـم الـذي تـم تقييمـه بواسـطة  VASبشـكل ملحـوظ
( )P<0.001من متوسط  VAS:7.29 ± 1.04قبل رأب العمود الفقري إلى متوسط  VAS 3.25 ± 0.75أسبوع واحد
شـهرا بعـد الجراحـة)  ،ومتوسـط  1.13 ± 3.11فـي
بعـد جراحـة العمـود الفقـري  ،والمتوسـط  -0.66 + 1.68فـي 12
ً
شهرا بعد الجراحة .في الدراسة الحالية  ،تحسن مؤشر اوزويسترى ODIبشكل ملحوظ من
المتابعة النهائية بعد 24
ً
شـهرا بعـد الجراحـة و
متوسـط  ODIقبـل العمليـة 12.35 40.75 :الـى متوسـط  3.15 ± 16.89بعـد الجراحـة فـي 12
ً
شهرا بعد الجراحة ( P<0.000مهم للغاية)
 0.914 ± 21.20في النهاية بعد 24
ً

الخالصـة :تـم مالحظـة تخفيـف اآلالم بشـكل سـريع وكبيـر وتحسـين جـودة الحيـاة بوضـوح بعـد جراحـة رأب الفقـرات
( ، )PVوتـم الحفـاظ علـى هـذه التحسـينات لمـدة تصـل إلـى عـام واحـد فـي معظم الحاالت بعدها تقـل كفاءه العالج
لتطـور المـرض .يمكـن إجـراء  PVبكفـاءة وفعاليـة فـي حـاالت كسـور هشاشـة العظـام التـي يسـببها السـتيرويد لعالج
آالم الظهر الشديدة دون مضاعفات كبيرة.
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